Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AGEN 
Agenus Inc (AGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: AGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.33
1 Year Target Price $12.33
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.3% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 142.75M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 5 | Beta 1.44 | 52 Weeks Range 1.38 - 7.34 | Updated Date 09/14/2025 |
52 Weeks Range 1.38 - 7.34 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -162.69% | Operating Margin (TTM) -65.32% |
Management Effectiveness
Return on Assets (TTM) -23.93% | Return on Equity (TTM) -1278.83% |
Valuation
Trailing PE - | Forward PE 3.52 | Enterprise Value 223745203 | Price to Sales(TTM) 1.4 |
Enterprise Value 223745203 | Price to Sales(TTM) 1.4 | ||
Enterprise Value to Revenue 2.2 | Enterprise Value to EBITDA -2.42 | Shares Outstanding 31864100 | Shares Floating 31319550 |
Shares Outstanding 31864100 | Shares Floating 31319550 | ||
Percent Insiders 1.71 | Percent Institutions 30.11 |
Upturn AI SWOT
Agenus Inc
Company Overview
History and Background
Agenus Inc. (AGEN) is a biotechnology company focused on developing and commercializing immuno-oncology products. Founded in 1994, the company has evolved from a focus on vaccine adjuvants to a broader platform of immune-modulating antibodies and cell therapies.
Core Business Areas
- Antibody Programs: Agenus develops and commercializes antibodies designed to activate or block immune checkpoints to enhance anti-tumor responses.
- Cell Therapy Programs: The company is developing cell therapies, including adoptive cell transfer (ACT) therapies, to treat various cancers.
- Adjuvants: Agenus continues to develop and commercialize vaccine adjuvants to enhance immune responses to vaccines.
Leadership and Structure
Agenus is led by Dr. Garo H. Armen as Chairman and CEO. The organizational structure includes research and development, clinical operations, commercialization, and administrative functions.
Top Products and Market Share
Key Offerings
- BAL-0891: A pro-drug microtubule-disrupting agent, used in various trials. Market share information unavailable. Competitors include companies developing other microtubule inhibitors like Bristol Myers Squibb (BMS) with Taxol and others.
- AGEN1181: An anti-CTLA-4 antibody designed to enhance anti-tumor immunity. Market share information unavailable as it's in development. Competitors include Bristol Myers Squibb (BMS) with Yervoy (ipilimumab).
- QS-21 Stimulon adjuvant: A key component of several approved vaccines. Revenue is project to be $8.5 million. GSK is a key partner utilizing QS-21 in its shingles vaccine, Shingrix. Competitors include other adjuvant developers.
Market Dynamics
Industry Overview
The immuno-oncology industry is experiencing rapid growth, driven by the increasing understanding of the role of the immune system in cancer treatment. Key trends include the development of novel immune checkpoint inhibitors, cell therapies, and combination therapies.
Positioning
Agenus is positioned as an innovative immuno-oncology company with a diverse pipeline of antibody and cell therapy candidates. Its competitive advantage lies in its differentiated approach to immune modulation and its partnerships with leading pharmaceutical companies.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Agenus is positioned to capture a portion of this TAM through its development of innovative immunotherapies.
Upturn SWOT Analysis
Strengths
- Diverse pipeline of immuno-oncology assets
- Strong expertise in antibody and cell therapy development
- Partnerships with leading pharmaceutical companies
- Innovative technology platforms
Weaknesses
- Limited commercial infrastructure
- Reliance on partnerships for revenue
- High cash burn rate
- Stock dilution
Opportunities
- Expansion of existing partnerships
- Approval of key pipeline assets
- Strategic acquisitions
- Development of novel combination therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- BMS
- MRK
- PFE
- GSK
Competitive Landscape
Agenus faces intense competition from larger pharmaceutical companies with greater resources and established market positions. However, Agenus's innovative technology platforms and differentiated approach to immune modulation provide a competitive edge.
Major Acquisitions
4-Antibody AG
- Year: 2014
- Acquisition Price (USD millions): 15
- Strategic Rationale: Acquired a fully human antibody discovery platform. Provided Agenus with access to a diverse library of human antibodies, accelerating its drug discovery efforts.
Growth Trajectory and Initiatives
Historical Growth: Agenus's historical growth has been driven by its research and development activities and its partnerships with larger pharmaceutical companies.
Future Projections: Future growth projections depend on the success of its pipeline assets and the expansion of its partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the advancement of its AGEN1181 and BAL-0891 programs and the expansion of its cell therapy capabilities.
Summary
Agenus is a biotechnology firm with a diversified pipeline of immuno-oncology assets, primarily antibody and cell therapy programs. The company's historical reliance on partnerships for revenue, combined with a consistent high cash burn rate, present significant challenges. Recent strategic initiatives to develop novel combination therapies have the potential to significantly increase the value of the company. Agenus needs to successfully commercialize their drugs and continue to acquire market share in order to improve its position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Agenus Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agenus Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-02-04 | Founder, Executive Chairman & CEO Dr. Garo H. Armen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.agenusbio.com |
Full time employees 316 | Website https://www.agenusbio.com | ||
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.